Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus.

Antimicrobial Agents and Chemotherapy
Christian JoukhadarGeorge M Eliopoulos

Abstract

With the current high prevalence of infection caused by methicillin-resistant Staphylococcus aureus (MRSA) strains but in light of the general belief that beta-lactam antibiotics are more effective than vancomycin against infections caused by methicillin-susceptible S. aureus (MSSA) isolates, clinicians may utilize antistaphylococcal penicillins in combination with vancomycin for the empirical treatment of S. aureus infections. Vancomycin is considered to kill MSSA more slowly than oxacillin. Thus, we sought to evaluate the interaction of the combination of oxacillin and vancomycin on bacterial killing in vitro. Ten clinical isolates of MSSA isolated in the year 2000 were investigated. The killing observed at 24 h by vancomycin at 20 microg/ml, oxacillin at 16 microg/ml, or the combination did not differ (approximately 2.5 to 3.5 log10 CFU/ml). In a separate experiment, we assessed bacterial killing in a dynamic model simulating the free plasma concentration profiles expected following the administration of a combination of vancomycin at 1 g every 12 h and oxacillin at 1 g every 6 h. The time-kill profiles of these regimens against S. aureus ATCC 29213 were comparable to those observed in the fixed-concentration experiments. Us...Continue Reading

References

Oct 11, 1992·Antimicrobial Agents and Chemotherapy·E CercenadoR C Moellering
Jun 1, 1990·Antimicrobial Agents and Chemotherapy·P M Small, H F Chambers
Jan 1, 1966·British Journal of Diseases of the Chest·G W AllanW F Tyrrell
Apr 1, 1980·Journal of Clinical Pharmacology·D J KrogstadD J Greenblatt
Apr 19, 2000·Antimicrobial Agents and Chemotherapy·B E DomarackiR A Venezia
Feb 11, 2003·Chest·Anne J KrantzDaniel O Hryhorczuk
Oct 25, 2003·Antimicrobial Agents and Chemotherapy·Julie A WuJohn F Kokai-Kun
Feb 24, 2006·Antimicrobial Agents and Chemotherapy·Maritza Barcia-MacayFrançoise Van Bambeke
Aug 18, 2006·The New England Journal of Medicine·Vance G FowlerUNKNOWN S. aureus Endocarditis and Bacteremia Study Group
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martin E StryjewskiUNKNOWN Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study

❮ Previous
Next ❯

Citations

Aug 30, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kevin W McConeghyKeith A Rodvold
Apr 1, 2016·Trials·Steven Y C TongUNKNOWN CAMERA2 study group and the Australasian Society for Infectious Diseases Clinical Research Network
Oct 25, 2016·Nature Microbiology·Vera PaderAndrew M Edwards
Feb 6, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Lukas StulikEszter Nagy
Oct 8, 2020·Nature Reviews. Microbiology·Fernando Baquero, Bruce R Levin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.